Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting


Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire

WALTHAM, Mass., May 27, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced that clinical trial data on entinostat will be presented in two posters during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30 - June 3, 2014, in Chicago.

The first poster, titled "Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer," is being presented by Roisin M. Connolly, M.D, assistant professor of oncology at the Kimmel Comprehensive Cancer Center at Johns Hopkins University. The second, being presented by Denise A. Yardley, M.D, an oncologist at the Sarah Cannon Research Institute, is titled "A phase 1 study to assess the food effect on the pharmacokinetics (PK) of entinostat."

Presentations are as follows:



Abstract #:    

569

Title:         

Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer

Presenter:  

Roisin M. Connolly, M.D.

When:        

Monday, June 2, 8:00 a.m.-11:45 a.m. CDT

Session Title: 

Breast Cancer - HER2/ER

Location:      

S Hall A2, Board 33



Abstract #:    

591

Title:             

A phase 1 study to assess the food effect on the pharmacokinetics (PK) of entinostat

Presenter:      

Denise A. Yardley, M.D.

When:            

Monday, June 2, 8:00 a.m.-11:45 a.m. CDT

Session Title:  

Breast Cancer - HER2/ER

Location:      

S Hall A2, Board 55

About Syndax Pharmaceuticals

Syndax is developing entinostat for the treatment of patients with therapy-resistant cancers. Entinostat is designed to prolong the effectiveness of current cancer treatments through an epigenetic mechanism and has been designated a Breakthrough Therapy by the FDA when used in combination with exemestane in estrogen receptor positive metastatic breast cancer. Entinostat is an oral, selective HDAC inhibitor that is being evaluated in combination with exemestane in a pivotal Phase 3 clinical study for the treatment of hormone receptor positive metastatic breast cancer. Syndax holds rights to entinostat in all major markets.

Corporate Contact:
Bob Goodenow
Chief Business Officer
Syndax Pharmaceuticals
(781) 419-1418
BGoodenow@Syndax.com

Investor Contact:
Robert Flamm, Ph.D.
Russo Partners
(212) 845-4226
robert.flamm@russopartnersllc.com

Media Contacts:
David Schull or Matt Middleman, M.D.
Russo Partners
(212) 845-4271
(212) 845-4272
david.schull@russopartnersllc.com 
matt.middleman@russopartnersllc.com

SOURCE Syndax Pharmaceuticals, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here